ArticleCureus2025
Neural Epidermal Growth Factor-Like 1 (NELL-1)-Associated Membranous Nephropathy: A Clinical and Outcome-Based Study From a Tertiary Care Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Clinicopathologic Study of Neural Epidermal Growth Factor-Like 1-Associated Membranous Nephropathy in a Chinese Cohort.Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMembranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, with neural epidermal growth factor-like 1 (NELL-1) identified as a novel target antigen in a subset of cases. This study aimed to evaluate the clinical profile, secondary associations, treatment, and outcomes of NELL-1-associated MN in a single-center cohort.
methodsWe conducted a retrospective observational study at a tertiary care center, reviewing all patients diagnosed with MN between January 2022 and April 2024. Patients with NELL-1-positive MN on renal biopsy immunohistochemistry were included. Clinical data, secondary causes (autoimmune diseases, toxic exposures, malignancies), treatments, and outcomes (remission status, proteinuria, serum albumin) were analyzed.
resultsAmong 65 MN patients, 12 (18.5%) had NELL-1-associated MN (66.7% female; median age 34 years). Secondary associations included exposure to mercury-containing skin-whitening cream in three patients (25%), malignancy in two (16.7%), and psoriasis in one (8.3%), while six patients (50%) had primary (idiopathic) NELL-1-associated MN. Initial therapy was conservative (renin-angiotensin system blockade and supportive care) in most; seven patients ultimately required immunosuppressive therapy due to persistent nephrotic syndrome or secondary causes. Over a mean follow-up of 22.9 ± 10.6 months, proteinuria significantly decreased (from 5.7 ± 4.3 g/day to 0.5 ± 0.7 g/day; p = 0.002), and serum albumin improved (2.7 ± 1.0 g/dL to 4.0 ± 0.5 g/dL; p = 0.006). By the last follow-up, eight patients (66.7%) achieved complete remission and three (25%) partial remission; one patient died during follow-up.
conclusionNELL-1-associated MN encompasses a heterogeneous spectrum of primary and secondary cases. Identifying inciting factors such as toxic exposures or malignancies is crucial, as withdrawal or treatment of the underlying cause can lead to remission. A majority of patients achieved remission with supportive care and/or immunosuppression, but relapses can occur. Long-term follow-up and patient education are essential. Larger studies are needed to inform optimal management strategies for NELL-1-associated MN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.